Inventiva Sa (IVA)

Currency in USD
5.600
+0.090(+1.63%)
Real-time Data·
IVA is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
5.4405.790
52 wk Range
2.8547.983
Key Statistics
Prev. Close
5.51
Open
5.53
Day's Range
5.44-5.79
52 wk Range
2.854-7.983
Volume
113.27K
Average Vol. (3m)
442.29K
1-Year Change
64.6091%
Book Value / Share
-0.05
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
IVA Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
15.126
Upside
+170.11%
Members' Sentiments
Bearish
Bullish
ProTips
Analysts anticipate sales decline in the current year

Inventiva Sa News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Strong Buy
Moving Averages
Strong Buy

Inventiva S.A., a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) and other diseases in France and internationally. The company develops Lanifibranor, a novel pan-peroxisome proliferator-activated receptor agonist that is in the NATiV3 Phase 3 clinical trial to treat adult patients with MASH; and Odiparcil for the treatment of patients with mucopolysaccharidoses. It also develops TGF-ß, a pre-clinical program for the treatment of idiopathic pulmonary fibrosis. The company was incorporated in 2011 and is headquartered in Daix, France.

Inventiva Sa Earnings Call Summary for Q4/2025

  • Inventiva reported Q4 2025 EPS of -$0.378, missing estimates of -$0.3436 by 10.01%; stock fell 4.56% in pre-market trading to $5.23.
  • Company maintains €231M cash position as of Dec 31, 2025, with runway projected through mid-Q1 2027 or mid-Q3 2027 if warrants exercised.
  • Strategic focus remains on lead candidate lanifibranor for MASH treatment, with clinical trials showing promising results amid competitive landscape.
  • Stock trades near 52-week low despite 86% annual return; analysts maintain price targets ranging from $8.80 to $26, suggesting potential upside.
  • Management emphasized strong cash position supports ongoing development and commercialization efforts; no revenue disclosed for quarter.
Last Updated: 03/31/2026, 09:12 AM
Read Full Transcript

Compare IVA to Peers and Sector

Metrics to compare
IVA
Peers
Sector
Relationship
P/E Ratio
−2.5x−2.9x−0.5x
PEG Ratio
−0.06−0.030.00
Price / Book
−98.6x0.9x2.6x
Price / LTM Sales
110.9x12.0x3.2x
Upside (Analyst Target)
155.4%172.7%47.6%
Fair Value Upside
Unlock13.6%6.1%Unlock

Analyst Ratings

13 Buy
0 Hold
0 Sell
Ratings:
13 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 15.126
(+170.11% Upside)
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate
Piper Sandler
Buy26.00+365.95%-MaintainApr 07, 2026
Leerink Partners
Buy12.00+115.05%-MaintainMar 31, 2026
Stifel
Buy15.00+168.82%17.00MaintainMar 31, 2026
Truist Securities
Buy13.00+132.97%-New CoverageMar 18, 2026
H.C. Wainwright
Buy24.00+330.11%-MaintainJan 28, 2026

Earnings

Latest Release
Mar 30, 2026
EPS / Forecast
-1.07 / -0.34
Revenue / Forecast
3.16M / --
EPS Revisions
Last 90 days

IVA Income Statement

People Also Watch

3.61
ALVO
+2.27%
14.96
VRDN
-1.55%
5.225
TSHA
+10.93%
824.48
LITE
-3.32%

FAQ

What Is the Inventiva (IVA) Stock Price Today?

The Inventiva stock price today is 5.600 USD.

What Stock Exchange Does Inventiva Trade On?

Inventiva is listed and trades on the Nasdaq Stock Exchange.

What Is the Stock Symbol for Inventiva?

The stock symbol for Inventiva is "IVA."

What Is the Inventiva Market Cap?

As of today, Inventiva market cap is 1.030B USD.

What Is Inventiva's Earnings Per Share (TTM)?

The Inventiva EPS (TTM) is -1.896.

When Is the Next Inventiva Earnings Date?

Inventiva will release its next earnings report on May 26, 2026.

From a Technical Analysis Perspective, Is IVA a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Neutral.

How Many Times Has Inventiva Stock Split?

Inventiva has split 0 times.

How Many Employees Does Inventiva Have?

Inventiva has 84 employees.

What is the current trading status of Inventiva (IVA)?

As of Apr 15, 2026, Inventiva (IVA) is trading at a price of 5.600 USD, with a previous close of 5.510 USD. The stock has fluctuated within a day range of 5.440 USD to 5.790 USD, while its 52-week range spans from 2.854 USD to 7.983 USD.

What Is Inventiva (IVA) Price Target According to Analysts?

The average 12-month price target for Inventiva is 15.126 USD, with a high estimate of 26 USD and a low estimate of 8.8 USD. 13 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Strong Buy. The stock has an +170.11% Upside potential.

What Is the IVA After Hours Price?

IVA's last after hours stock price is 5.540 USD, the stock has decreased by 0.030, or 0.540%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.